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Lipoprotein(a) (Lp[a]) is a circulating lipoprotein with proatherogenic, proin-flammatory, and possibly prothrombotic properties. Circulating Lp(a) levels are largely genetically determined, in particular, by the LPA gene. As such, genetic 
variants at the LPA locus can serve as instrumental variables for investigating the 
clinical effects of circulating Lp(a) levels. Mendelian randomization (MR) studies 
have shown that elevated Lp(a) levels are associated with a higher risk of coronary 
artery disease1–3 and aortic valve stenosis.2–4 Evidence on the causal role of elevated 
Lp(a) levels for other atherosclerotic and specific valvular diseases is limited, al-
though there are MR data supporting a positive association between genetically 
predicted Lp(a) levels and peripheral artery disease.2,3 Whether Lp(a) is causally 
related to thrombotic disease and cerebrovascular disease remains unclear.2,3,5
In this study, we used the UK Biobank cohort to perform an MR investigation 
into the causal effects of circulating Lp(a) levels on atherosclerotic, cerebrovascular, 
thrombotic, and valvular diseases. Because a recent MR study provided evidence 
of an inverse association of Lp(a) levels with Alzheimer disease,5 we additionally 
explored whether genetically predicted Lp(a) levels are associated with Alzheimer 
disease and dementia.
This study included 367 586 unrelated European-descent UK Biobank partici-
pants. Outcomes were defined based on International Classification of Diseases 
and Related Health Problems codes, and self-reported data validated by interview 
with a nurse. Incident cases were recorded until March 31, 2017, and deaths were 
recorded until February 14, 2018. The UK Biobank was approved by the North 
West Multicentre Research Ethics Committee, and all participants provided written 
informed consent.
We used a genetic instrument comprising 43 single-nucleotide polymorphisms 
(at the LPA locus) conditionally associated with Lp(a) levels at genome-wide sig-
nificance in 27 540 European-descent participants from the CHD Exome+ Consor-
tium (no overlap with UK Biobank).1 Genetic associations with Lp(a) were taken 
from the CHD Exome+ Consortium and were additionally validated in UK Biobank. 
The instrument explained 61.0% of the variance in Lp(a) levels in UK Biobank. 
Effect sizes of the single-nucleotide polymorphisms–outcome associations were 
estimated in UK Biobank using logistic regression under an additive model with 
adjustment for age, sex, and 10 principal components of ancestry. MR estimates 
were obtained using the inverse variance–weighted method with adjustment for 
correlations among the single-nucleotide polymorphisms.
The associations with the outcomes per genetically predicted 50-mg/dL in-
crease in Lp(a) levels are shown in the Figure. Our results support a strong causal 
relationship between Lp(a) levels and coronary artery disease. The observed odds 
ratio was 1.36 (95% CI, 1.32–1.40), which is similar to the previously observed 
association in the CHD Exome+ Consortium (odds ratio rescaled per 50-mg/dL 
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increment of Lp[a] levels, 1.35 [95% CI, 1.29–1.41]).1 
We observed even stronger associations between ge-
netically predicted Lp(a) levels and peripheral artery 
disease, abdominal aortic aneurysm, occlusion or ste-
nosis of precerebral arteries, and aortic stenosis with 
or without regurgitation. Novel findings were positive 
associations of genetically predicted Lp(a) levels with 
both aortic and mitral regurgitation. Our findings 
support a previously reported modest association be-
tween genetically predicted Lp(a) levels and ischemic 
stroke,2,5 and a null association with venous thrombo-
embolism as well.2,3 We found null associations with 
hemorrhagic stroke subtypes. Although we found 
null associations with Alzheimer disease and vascular 
dementia, possibly attributable to lack of power, our 
study revealed a weak inverse association of geneti-
cally predicted Lp(a) levels with self-reported parental 
history of Alzheimer disease or dementia. All results 
were consistent when using a genetic instrument 
comprising the 2 single-nucleotide polymorphisms 
(rs10455872 and rs3798220) used in several previous 
MR studies.3–5
The mechanism behind the associations of Lp(a) lev-
els with aortic regurgitation without concomitant aor-
tic stenosis and mitral regurgitation is unclear, but it 
could possibly be related to degenerative change from 
calcific aortic valve disease known to be associated 
with Lp(a) levels. Aortic valve sclerosis represents a sig-
nificant proportion of the underlying pathogenesis of 
isolated aortic regurgitation. Likewise, mitral annular 
calcification may interfere with mitral valve closure and 
increase mitral regurgitation, which represented >90% 
of all mitral valve disease cases. Last, aortic stenosis 
may also create or worsen mitral regurgitation.
An advantage of our study is that we assess and 
compare the associations of genetically predicted Lp(a) 
levels with atherosclerotic, cerebrovascular, thrombotic, 
and valvular diseases in a single population of individu-
als of European descent. This, however, limited the gen-
eralizability of our results to other populations. Another 
limitation is that outcomes were defined in part by vali-
dated self-reported disease, which could lead to some 
misclassification of outcome.
In conclusion, this MR study supported Lp(a) as a 
causal risk factor for atherosclerotic and valvular dis-
eases but not for thrombotic disease and hemorrhagic 
stroke subtypes. These findings may be used to inform 
the design of further research toward the treatment 
and prevention of atherosclerotic and valvular diseases. 
Whether lowered Lp(a) levels increase the risk of de-
mentia needs further investigation.
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Figure. Associations of genetically predicted Lp(a) levels with atherosclerotic, valvular, thrombotic, and cerebrovascular diseases and dementia.
*Excluding rheumatic valvular disorders. †Vascular dementia and Alzheimer disease are defined based on an individual’s routinely collected medical outcomes, 
whereas parental Alzheimer disease or dementia is defined as self-report of a family history of Alzheimer disease or dementia. Genetic associations with parental 
Alzheimer disease or dementia are less likely to suffer from selection bias or survivor bias, because participation in UK Biobank is less likely to be influenced by the 
medical history of an individual’s parents. Lp(a) indicates lipoprotein(a); and OR, odds ratio.
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